These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35705270)

  • 1. Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.
    Kurita Y; Kobayashi N; Hara K; Mizuno N; Kuwahara T; Okuno N; Haba S; Tokuhisa M; Hasegawa S; Sato T; Hosono K; Kato S; Kessoku T; Endo I; Shimizu Y; Kubota K; Nakajima A; Ichikawa Y; Niwa Y
    Intern Med; 2023 Jan; 62(2):159-167. PubMed ID: 35705270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
    Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.
    Zhu L; Ye X; She Y; Liu W; Hasegawa K; Rossi RE; Du Q; Zhai Q
    J Gastrointest Oncol; 2024 Apr; 15(2):689-709. PubMed ID: 38756630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options.
    Kurita Y; Kobayashi N; Hara K; Mizuno N; Kuwahara T; Okuno N; Haba S; Tokuhisa M; Hasegawa S; Kubota K; Nakajima A; Ichikawa Y
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms.
    Quan L; Liu Y; Cui W; Wang X; Zhang W; Wang Z; Guo C; Lu C; Hu F; Chen X
    Lipids Health Dis; 2022 Jul; 21(1):58. PubMed ID: 35842659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
    Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin and everolimus in neuroendocrine tumours: A synergic effect?
    Hue-Fontaine L; Lemelin A; Forestier J; Raverot G; Milot L; Robinson P; Borson-Chazot F; Lombard-Bohas C; Walter T
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):954-960. PubMed ID: 32146090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.
    Lee KJ; Cho JH; Lee SH; Song SY; Lee KH; Jeong S; Ryu JK; Woo SM; Bang S; Lee JK; Lee TH; Paik WH; Kim YT; Lee WJ
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):799-805. PubMed ID: 28884280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
    Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
    Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
    Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
    J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
    Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
    Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
    Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
    Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
    J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Morken S; Langer SW; Sundlöv A; Vestermark LW; Ladekarl M; Hjortland GO; Svensson JB; Tabaksblat EM; Haslerud TM; Assmus J; Detlefsen S; Couvelard A; Perren A; Sorbye H
    Br J Cancer; 2023 Dec; 129(12):1930-1939. PubMed ID: 37872405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade.
    Guo C; Zhuge X; Wang Z; Wang Q; Sun K; Feng Z; Chen X
    Abdom Radiol (NY); 2019 Feb; 44(2):576-585. PubMed ID: 30182253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.